Verona Pharma PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Verona Pharma achieved its first profitable quarter driven by strong Ohtuvayre sales, as its acquisition by Merck for $10 billion progresses towards a Q4 2025 close.
Verona Pharma's Q1 2025 results highlight a successful Ohtuvayre launch with $71.3 million in product sales and continued pipeline development.
Verona Pharma reports its first product sales of $5.6 million following the launch of Ohtuvayre in the third quarter of 2024, while also increasing research and development spending.
10-Q: Verona Pharma Reports Second Quarter 2024 Results, Highlights Ohtuvayre Launch and Pipeline Progress
Verona Pharma's Q2 2024 report details the launch of Ohtuvayre, significant financial activities, and advancements in their clinical pipeline.
Verona Pharma's Q1 2024 results show increased spending on commercial preparations and a net loss of $25.8 million, while the company secures a new $250 million financing package.